The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">CK2 form</td><td align="center">Activity %</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">CK2<i>α</i> (Human)</td><td align="center">42%</td></tr><tr><td align="left">CK2<i>α</i>′ (Human)</td><td align="center">38%</td></tr><tr><td align="left">CK2<i>α</i> (Zea mays)</td><td align="center">33%</td></tr><tr><td align="center" colspan="2"><hr/></td></tr><tr><td align="left">CK2<i>α</i><sub>2</sub><i>β</i><sub>2</sub> (Human)</td><td align="center">10%</td></tr><tr><td align="left">CK2<svg height="15.2701pt" id="M6" style="vertical-align:-3.834pt" version="1.1" viewbox="-0.0498162 -11.4361 12.1315 15.2701" width="12.1315pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M545 106L524 126C493 85 467 65 455 65C438 65 427 113 405 238C448 295 498 362 543 439L533 448L478 435C453 386 423 331 398 295H395C370 404 347 448 282 448C169 448 23 309 23 153C23 54 65 -12 128 -12C203 -12 283 70 339 155H341C360 29 380 -12 411 -12C444 -12 491 11 545 106ZM333 204C265 95 210 54 169 54C137 54 113 96 113 171C113 302 191 405 252 405C301 405 318 306 333 204Z" id="g113-223"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="568" vert-adv-y="568"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,7.385,-5.741)"><path d="M310 541L304 571C290 586 211 619 185 610L80 76L131 52L310 541Z" id="g50-31"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="361" vert-adv-y="361"></glyph.data></g><g transform="matrix(.0091,0,0,-0.0091,7.059,3.784)"><path d="M414 144C384 79 371 75 317 75H135L276 221C367 316 408 376 408 465C408 570 327 635 237 635C179 635 131 609 100 575L42 494L67 471C94 510 138 565 205 565C277 565 321 517 321 435C321 348 258 270 195 195C146 137 88 81 33 26V0H411C423 44 433 88 446 135L414 144Z" id="g50-51"></path><glyph.data ascent="3443" descent="-2856" horiz-adv-x="487" vert-adv-y="487"></glyph.data></g></svg><i>β</i><sub>2</sub> (Human)</td><td align="center">14%</td></tr><tr><td align="left">nCK2 (Rat liver)</td><td align="center">6%</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Residual catalytic activity (determined at 1 <svg height="9.39034pt" id="M5" style="vertical-align:-3.42943pt" version="1.1" viewbox="-0.0498162 -5.96091 7.34167 9.39034" width="7.34167pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M538 96L524 119C492 88 454 63 446 63C439 63 434 70 440 101C463 223 491 341 518 448H508L433 422L401 276C355 192 240 56 188 56C163 56 154 89 163 133C184 233 207 338 235 443L230 448L152 424L58 17C40 -60 23 -143 23 -185C23 -241 42 -261 63 -261C92 -261 117 -241 125 -227L124 -221C109 -209 89 -165 89 -103C89 -55 96 -13 105 26H107C121 -3 134 -12 151 -12C172 -12 194 -5 221 16C279 61 330 124 384 194H386C381 159 377 141 368 105C343 3 363 -12 383 -12C416 -12 486 35 538 96Z" id="g113-234"></path><glyph.data ascent="3473" descent="-2876" horiz-adv-x="555" vert-adv-y="555"></glyph.data></g></svg>M quinalizarin concentration) of different CK2 forms. 

BioMed Research International

The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation

Table 3